Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
Authors
Keywords
Hepatocellular carcinoma, Immune-checkpoint inhibitors, Computed tomography, Magnetic resonance imaging
Journal
EUROPEAN JOURNAL OF RADIOLOGY
Volume 135, Issue -, Pages 109484
Publisher
Elsevier BV
Online
2020-12-18
DOI
10.1016/j.ejrad.2020.109484
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma
- (2020) Ankur Sharma et al. CELL
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma
- (2019) Jordi Bruix et al. Nature Reviews Gastroenterology & Hepatology
- Heterogeneity of Hepatocellular Carcinoma on Imaging
- (2019) Jordi Rimola SEMINARS IN LIVER DISEASE
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- AASLD guidelines for the treatment of hepatocellular carcinoma
- (2017) Julie K. Heimbach et al. HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- RECIST — learning from the past to build the future
- (2016) Saskia Litière et al. Nature Reviews Clinical Oncology
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Multistep human hepatocarcinogenesis: correlation of imaging with pathology
- (2009) Masatoshi Kudo JOURNAL OF GASTROENTEROLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started